Evan Jones, Chairman and CEO
Mr. Jones is the Chairman and CEO of OpGen and also is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute.
Mr. Jones received a B.A. degree from the University of Colorado and an M.B.A. from The Wharton School, University of Pennsylvania.
Timothy J.R. Harris, Ph.D., Director
Dr. Harris is a science and business leader with nearly 40 years of experience guiding and leading laboratory work and scientists in a range of molecular research areas.
He is a molecular biologist and biochemist, and is currently a Venture Partner with SV Life Sciences and acting EVP R&D at Bioverativ. He was until March 2016, the SVP for Precision Medicine at Biogen. He was before that SVP of Translational Medicine at Biogen Idec. Until 2011, he was the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland which operates the National Cancer Institute’s leading center for cancer and AIDS research (now Frederick National Laboratory operated by Leidos Inc.,).
He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and he founded SGX Pharmaceuticals in 1999 (formerly Structural Genomix), where he built the company to more than 130 employees, raised $85M in capital, and generated more than $20M in revenue during six years as CEO before it was sold to Eli Lilly. Before founding SGX, Dr. Harris was Senior Vice President, Research and Development at Sequana/Axys. He began his scientific career working on animal viruses such as foot & mouth disease and was one of the first molecular biologists (1981) at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993.
He is currently on the Board of Directors of Opgen (Nasdaq: OPGN) and is a visiting Professor at Columbia University, New York.
Tina Nova, Ph.D., Director
Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manager of Illumina’s oncology business unit. From 2000 to 2014, Dr. Nova was a co-founder and director, president and chief executive officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation for nearly $0.5 billion in 2011. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc.
She currently serves on the board of directors for Arena Pharmaceuticals and Veracyte and is vice chairman of the board of directors for the newly formed Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children’s Hospital-San Diego.
Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine where she graduated with honors and a Ph.D. in Biochemistry from the University of California, Riverside.
David M. Rubin, Ph.D., Director
Dr. Rubin is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. Dr. Rubin has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. He holds board seats at Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx.
Dr. Rubin joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all Merck Research Laboratories (MRL) disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. He joined Merck from Cognia Corporation where he was CEO and President, and helped to develop it into one of the pioneer bioinformatics products company. Previously, he was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies.
Dr. Rubin holds a Ph.D. from Temple University in Molecular Biology and a B.A. from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Misti Ushio, Ph.D., Director
Dr. Ushio is CEO of TARA Biosystems. Prior to TARA Biosystems, Dr. Ushio was Chief Strategy Officer and Managing Director of Harris & Harris Group, which she joined in 2007. Prior to joining Harris & Harris Group, Dr. Ushio worked for Merck & Co. for over 10 years in the BioProcess Research & Development group, which focused on vaccines and biologics development. She also worked as a Technology Licensing Officer at Columbia University.
Dr. Ushio currently serves or has served on the boards of Accelerator-NYC, AgBiome, Enumeral Biomedical, Lodo Therapeutics, Petra Pharma, OpGen, Senova Systems and SynGlyco.
Her past investments include BioVex (acquired by Amgen), TetraVitae (acquired by Eastman) and Ancora Pharmaceuticals (acquired by Corden Pharma).
She graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering).